Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2000

View Archived Issues

Licensing opportunity from NIH: vaccinia virus vector for cancer therapy

Licensing opportunity from NIH: subunit vaccine for viral diseases

CytRx and Merck enter TranzFect agreement

Verteporfin shows promise in clinical trials for the treatment of skin cancer

MediGene to acquire NeuroVir

NeoTherapeutics to focus on higher doses of Neotrofin

Promising phase III results with Gliadel as first-line treatment of malignant glioma

Completion of Elan's acquisition of Dura announced

Genelabs Technologies and Watson enter collaboration and licensing agreement for lupus drug

Icos receives license from Stanford for novel antibiotic target

PDT with MV-6401 prevents neointimal formation following carotid artery angioplasty in rats

Selective ETA antagonism with TBC-3711 as a new approach to neonatal pulmonary hypertension

Hemodynamic effects and safety of conivaptan in advanced heart failure discussed at AHA meeting

AHA news: new MTP inhibitor markedly reduces postprandial fat absorption in humans

Phase I/II data indicate efficacy and safety of TP-10 in preventing post-CPB inflammation in infants

Acronycine analogue S-23906 confirmed as a potential development candidate for solid tumors

Trizivir anti-HIV therapy approved by FDA

Potential cellular mechanism for adverse cardiac effects of Herceptin described at AHA sessions

ALS treatment now available from Aventis in Canada

Chemokine receptor-modulating pyrrolidine derivatives described by Merck

Novel tetrahydropyridazines from Merck KGaA inhibit PDE4 and TNF

BASF presents small molecules with tyrosine kinase-inhibitory activity

European Commission grants orphan drug status to Mylotarg for treatment of AML

NOS inhibitors derived from lipoic acid described in recent patent by SCRAS

Series of selective Tgamma9delta2 lymphocyte inhibitors emerges from joint U.S.-French R&D

Promising first clinical data on NESP in anemic cancer patients presented at ESMO

SB's new ET receptor antagonists covered by U.S. patent

Naeja describes preparation, activity and use of new cathepsin inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...